CCC Intelligent Solutions Holdings Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CCC Intelligent Solutions Holdings Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.06B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $944.80M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $866.38M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $782.45M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $688.29M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $633.06M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $616.08M | Mar 1, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $776.81M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $713.80M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $636.16M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $568.51M | Feb 25, 2025 |
| FY2021 | Dec 31, 2021 | $139.39M | Mar 1, 2022 |
| FY2021 | Sep 30, 2021 | $118.78M | Mar 1, 2022 |
| FY2021 | Jun 30, 2021 | $121.28M | Mar 1, 2022 |
| FY2021 | Mar 31, 2021 | $113.20M | Mar 1, 2022 |
| FY2021 | Dec 31, 2020 | $112.07M | Mar 1, 2022 |
| FY2021 | Sep 30, 2020 | $107.30M | Mar 1, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.69M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $31.24M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($90.07M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $38.41M | Feb 25, 2025 |
| FY2021 | Dec 31, 2021 | ($57.87M) | Mar 1, 2022 |
| FY2021 | Sep 30, 2021 | ($189.78M) | Mar 1, 2022 |
| FY2021 | Jun 30, 2021 | $3.82M | Mar 1, 2022 |
| FY2021 | Mar 31, 2021 | ($5.08M) | Mar 1, 2022 |
| FY2021 | Dec 31, 2020 | $5.62M | Mar 1, 2022 |
| FY2020 | Sep 30, 2020 | ($81.47M) | May 14, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $93.84M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $80.11M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | ($23.93M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $51.92M | Feb 25, 2025 |
| FY2021 | Dec 31, 2021 | $15.30M | Mar 1, 2022 |
| FY2021 | Sep 30, 2021 | ($189.21M) | Mar 1, 2022 |
| FY2021 | Jun 30, 2021 | $22.00M | Mar 1, 2022 |
| FY2021 | Mar 31, 2021 | $7.24M | Mar 1, 2022 |
| FY2021 | Dec 31, 2020 | $24.13M | Mar 1, 2022 |
| FY2021 | Sep 30, 2020 | $23.09M | Mar 1, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $227.50M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $201.49M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $173.11M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $156.96M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $165.99M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $109.51M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $114.01M | Mar 1, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $315.48M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $283.89M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $250.03M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $199.91M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $127.34M | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | ($11.8K) | May 14, 2021 |
| FY2021 | Dec 31, 2019 | $66.30M | Mar 1, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $60.97M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $53.01M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $55.03M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $47.95M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $38.32M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $30.11M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $20.46M | Mar 1, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.57B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $3.18B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $3.05B | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $3.35B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $3.24B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $3.20B | Mar 1, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.79B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.16B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $1.25B | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $1.29B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.35B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $1.81B | Mar 1, 2022 |
| FY2020 | Sep 30, 2020 | $141.76M | May 14, 2021 |
| FY2020 | Aug 18, 2020 | $68.57M | May 14, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.79B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $2.00B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $1.78B | Feb 24, 2026 |
| FY2025 | Dec 31, 2022 | $2.05B | Feb 24, 2026 |
| FY2024 | Dec 31, 2021 | $1.87B | Feb 25, 2025 |
| FY2023 | Dec 31, 2020 | $1.37B | Feb 28, 2024 |
| FY2020 | Jul 2, 2020 | $0 | May 14, 2021 |
| FY2022 | Dec 31, 2019 | $1.38B | Mar 1, 2023 |
| FY2021 | Dec 31, 2018 | $1.57B | Mar 1, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.96B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.42B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $1.42B | Feb 24, 2026 |
| FY2025 | Dec 31, 2022 | $1.50B | Feb 24, 2026 |
| FY2023 | Dec 31, 2021 | $1.47B | Feb 28, 2024 |
| FY2021 | Dec 31, 2020 | $1.47B | Mar 1, 2022 |
| FY2021 | Dec 31, 2019 | $1.47B | Mar 1, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.70B) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($1.10B) | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | ($1.13B) | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | ($707.95M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($746.35M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | ($129.37M) | Mar 1, 2022 |
| FY2020 | Sep 30, 2020 | ($81.47M) | May 14, 2021 |
| FY2020 | Aug 18, 2020 | ($8.38M) | May 14, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $111.19M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $398.98M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $195.57M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $323.79M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $182.54M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $162.12M | Mar 1, 2022 |
| FY2021 | Dec 31, 2019 | $93.20M | Mar 1, 2022 |
| FY2021 | Dec 31, 2018 | $57.45M | Mar 1, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.29B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $776.00M | Feb 25, 2025 |
| FY2022 | Dec 31, 2022 | $792.00M | Mar 1, 2023 |
| FY2021 | Dec 31, 2021 | $800.00M | Mar 1, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 25, 2025 |
| FY2021 | Dec 31, 2021 | 0 | Mar 1, 2022 |
| FY2021 | Sep 30, 2021 | 0 | Mar 1, 2022 |
| FY2021 | Jun 30, 2021 | 0 | Mar 1, 2022 |
| FY2021 | Mar 31, 2021 | 0 | Mar 1, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Mar 1, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Mar 1, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 25, 2025 |
| FY2021 | Dec 31, 2021 | 0 | Mar 1, 2022 |
| FY2021 | Sep 30, 2021 | 0 | Mar 1, 2022 |
| FY2021 | Jun 30, 2021 | 0 | Mar 1, 2022 |
| FY2021 | Mar 31, 2021 | 0 | Mar 1, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Mar 1, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Mar 1, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 605.45M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 629.21M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | 603.13M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | 622.07M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 609.77M | Mar 1, 2023 |
| FY2021 | Sep 30, 2021 | 603.17M | Mar 1, 2022 |
| FY2021 | Dec 31, 2020 | 504.27M | Mar 1, 2022 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Aug 3, 2021 | $134.60M | Feb 28, 2024 |
| FY2023 | Mar 17, 2021 | $134.50M | Feb 28, 2024 |